SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Danaher completed a material private placement of CHF 2.26+ billion in senior unsecured notes across seven series with maturities from 2031 to 2056, with proceeds to be used for general corporate purposes including acquisitions and share repurchases.
View raw filing on EDGAR →PSEG completed a $500 million public offering of senior notes due 2031 on June 3, 2026. While debt issuances are material financing events affecting the registrant's capital structure and financial position, this disclosure does not fit neatly into the more specific event categories (it is not M&A, a dilutive equity issuance, or a covenant breach). The filing is a routine debt offering disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the Company's annual meeting held on May 28, 2026. Item 5.07 requires disclosure of the final voting results on two proposals: election of two Class II directors (Virginia Grebbien and Patricia Mulroy) and ratification of Ernst & Young LLP as independent auditor. Both proposals passed with detailed vote tallies provided, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Calumet's June 2, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of three Class II directors (Todd Borgmann, Daniel J. Sajkowski, Bradford T. Sanders), advisory approval of executive compensation, and ratification of Grant Thornton LLP as independent auditor. All three proposals passed with substantial majorities, making this a material disclosure of shareholder actions that affects the composition and governance of the company.
View raw filing on EDGAR →TD SYNNEX issued an unregistered warrant to Amazon.com NV Investment Holdings LLC for up to 3,238,066 shares of common stock, with vesting tied to payment thresholds under a commercial arrangement. The filing explicitly states the issuance is unregistered under the Securities Act and relies on Section 4(a)(2) exemption, which is the hallmark of a dilutive private placement. The warrant represents a material equity commitment to a major strategic partner and would significantly affect investor assessment of share dilution and capital structure.
View raw filing on EDGAR →This 8-K discloses the issuance of $5 billion in debt securities ($2.5B 4.972% Fixed/Floating Rate Notes due 2032 and $2.5B 5.425% Fixed/Floating Rate Notes due 2037) by Goldman Sachs on June 3, 2026 pursuant to its shelf registration. While debt issuances are material financing events affecting the registrant's capital structure and liquidity, they do not fit neatly into the standard taxonomy categories (not M&A, not dilutive equity, not a restatement or going-concern issue). This is a material capital markets transaction disclosed via Item 9.01 (Exhibits).
View raw filing on EDGAR →The disclosure announces a €950 million senior notes offering by IQVIA Inc. (wholly owned subsidiary) and refinancing of existing indebtedness. While this is a material financing event affecting the company's capital structure and debt profile, it is not a traditional M&A activity (acquisition, disposition, merger, or change of control). The event is material to investors but does not fit cleanly into the taxonomy; it is best classified as "other_material" rather than forcing it into ma_activity.
View raw filing on EDGAR →Vroom disclosed amendments to two material warehouse credit facilities on May 29, 2026. Amendment No. 28 to Warehouse Credit Facility One extends the Commitment Termination Date by one month (June 2 to July 2, 2026), while Amendment No. 10 to Warehouse Credit Facility Two reduces advance rates, lowers the Minimum Tangible Net Worth covenant, and adjusts liquidity calculations. These amendments to material financing arrangements would affect a reasonable investor's assessment of the company's liquidity and financial flexibility, but the disclosures do not clearly indicate a covenant breach, going-concern issue, or other more specific event type—making "other_material" the most appropriate classification.
View raw filing on EDGAR →TTM Technologies entered into a Second Amended & Restated Credit Agreement on June 1, 2026, materially restructuring its debt facilities through a repriced and upsized $400 million term loan facility and a new $1.0 billion revolving credit facility, while terminating two existing asset-based credit facilities (U.S. ABL and Asia ABL). This material refinancing constitutes a significant change to the company's capital structure and financial flexibility.
View raw filing on EDGAR →ATI Inc. announced the pricing of an unsecured senior notes offering (5.875% due 2033) on June 3, 2026. This is a material debt issuance that would affect investor assessment of the company's capital structure and financial obligations, but it does not fit neatly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or a financial restatement). The disclosure is appropriately classified as other_material.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Glaukos Corporation's annual meeting held on May 28, 2026, covering three proposals: election of two Class II directors, advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing presents final vote tallies for each matter, which is the quintessential content of Item 5.07 shareholder vote results disclosures and is material to investors assessing corporate governance and management accountability.
View raw filing on EDGAR →The filing discloses the appointment of Darin Rovell as Chief Accounting Officer effective June 22, 2026, following Board approval on June 1, 2026. While the section also details compensatory arrangements (base salary of $350,000, bonus opportunity, RSU grant of 325,000 shares, and severance terms), the principal disclosed action is the appointment of an officer to a named executive position. The compensation details are ancillary to the appointment itself.
View raw filing on EDGAR →The filing discloses an "operations and financial update" via press release filed with Canadian Securities Regulatory Authorities. While the Item 7.01 disclosure itself is vague and non-specific, the reference to a press release providing "operations and financial update" suggests material business information. Without access to the actual press release (Exhibit 99.1), the precise nature of the update cannot be determined—it could relate to earnings, material events, or other developments. Given the ambiguity and the Regulation FD safe-harbor language, this is classified as other_material rather than a more specific category.
View raw filing on EDGAR →The filing discloses completion of a material acquisition under Item 2.01: Richtech Robotics completed the purchase of a 79,325 square foot property in Las Vegas for $21,180,000 on May 29, 2026. The company intends to use the facility for warehousing, assembly, light manufacturing, R&D, and robotics-driven data collection—a strategic operational asset. This represents a significant capital deployment and material acquisition of assets.
View raw filing on EDGAR →USA Rare Earth entered into material definitive agreements with the U.S. Department of Commerce on June 3, 2026, comprising a Direct Funding Agreement ($277 million in direct awards) and a Loan Guarantee Agreement ($1.3 billion in guaranteed debt), totaling $1.6 billion in funding for five major capital projects. This transformative financing transaction fundamentally restructures USAR's capital structure and triggers significant equity raise requirements, covenants, and security interests in substantially all assets.
View raw filing on EDGAR →USA Rare Earth disclosed an unregistered sale of common stock and warrants pursuant to a Securities Issuance Agreement, representing a dilutive equity issuance that materially affects existing shareholders' ownership percentages and signals capital-raising activity at the registrant.
View raw filing on EDGAR →The Company increased the maximum aggregate offering price under an At The Market (ATM) offering agreement by $6,829,000 in additional common stock, with approximately $9,279,067 already sold to date. ATM offerings are equity issuances that dilute existing shareholders and are material capital-raising events, particularly for smaller-cap issuers like Rocket One Inc. The filing of a prospectus supplement confirms this is a registered dilutive equity offering.
View raw filing on EDGAR →Major General Malcolm Frost's appointment to the Advisory Board is disclosed as a material personnel action. While an advisory board position is typically less material than an officer or director appointment, the specific focus on guiding technical development of the Company's core infrastructure for orbital economy and space/defense applications suggests this is a strategically significant appointment that would inform a reasonable investor's assessment of the Company's technical direction and capabilities.
View raw filing on EDGAR →The filing discloses entry into Amendment No. 1 to an Intellectual Property License Agreement with BP United on June 1, 2026, which materially modifies the original IP Agreement dated May 12, 2026. The amendment restructures consideration (retaining $5M cash, issuing vesting shares), eliminates a planned Supply Agreement, and substitutes manufacturing and consulting services. While Item 1.01 is titled "Entry into a Material Definitive Agreement," the substance is an amendment that restructures an existing deal rather than a standalone M&A transaction, acquisition, or disposition. The materiality to investors is clear (cash retention, equity issuance, operational restructuring), but the event does not fit cleanly into the M&A taxonomy categories.
View raw filing on EDGAR →Ondas Inc. disclosed unregistered sales of equity securities (the "Shares") exempt under Regulation S to non-U.S. investors, representing a dilutive issuance to existing shareholders.
View raw filing on EDGAR →Ondas Inc. completed or substantially advanced its acquisition of Omnisys Ltd., an Israeli company, with 2,112,674 shares issued to stockholders in connection with the transaction and subsequently registered for resale.
View raw filing on EDGAR →The filing discloses two material debt events: (1) Amendment No. 1 extending the maturity of a $1.25M senior note from June 30, 2026 to November 15, 2026 and removing a prior event of default related to preferred share authorization; and (2) issuance of $312.5M in aggregate principal unsecured promissory notes due November 15, 2026 for $250K proceeds. While Item 1.01 (material definitive agreement) and Item 2.03 (direct financial obligation) are disclosed, the substance involves debt restructuring and new financing that does not cleanly fit the taxonomy categories—it is neither a covenant breach (no violation alleged), nor a going-concern disclosure, nor a dilutive issuance (debt, not equity). The extension of maturity and removal of a prior default event suggest financial stress, making this material to investors but best classified as other_material given the hybrid nature of debt amendment and new financing.
View raw filing on EDGAR →The filing discloses a $40 million revolving line of credit from Endeavor Blockchain (controlled by Executive Chairman Josh Kilgore) at 12% interest, payable on demand, with customary events of default including covenant violations and bankruptcy triggers. While the primary disclosure is the creation of a direct financial obligation (Item 2.03), the demand-payable structure, high interest rate, and related-party nature suggest potential financial stress. However, this is a new credit facility, not a breach of existing covenants, making the classification ambiguous between a direct obligation and a signal of underlying distress.
View raw filing on EDGAR →Tribeca Strategic Acquisition Corp. completed its IPO on June 1, 2026, raising $140 million through the sale of 14 million units and entering into multiple material definitive agreements including underwriting, rights, trust, registration rights, and private placement agreements in connection with the SPAC formation.
View raw filing on EDGAR →The company completed unregistered private placements of 470,000 Private Placement Units ($4.7M) to the Sponsor and BTIG, LLC under Section 4(a)(2) exemptions, plus 140,000 Representative Shares to underwriters, concurrent with the IPO.
View raw filing on EDGAR →The company appointed four directors (Dange, Dunham, Oakley, Tomba) to the board on May 28, 2026, appointed Timothy Ramdeen as Chairman and CEO, and appointed Sukhvinder Gill as Chief Financial Officer and COO in connection with the IPO.
View raw filing on EDGAR →The Company entered into a Software Development Agreement with Nexe Cloud Limited on May 28, 2026, to design and develop an enterprise business intelligence system spanning six major workstreams (architecture, infrastructure, data warehouse, integration, visualization, and analytics). While Item 1.01 typically covers M&A activity, this is a material service contract for enterprise software development with a first milestone payment of $300,000 and a one-year term. The scope and strategic importance (centralized intelligent ecosystem supporting enterprise-wide planning) suggest materiality, but the event does not fit the M&A taxonomy (no acquisition, merger, or change of control) and is best classified as other_material.
View raw filing on EDGAR →Matthew K. Szot departed as Chief Financial Officer effective May 28, 2026, following a mutual agreement with the Company. While the filing also discloses the interim appointment of Quang X. Pham as interim CFO and severance arrangements totaling approximately $603,709 in cash and accelerated equity vesting, the principal disclosed action centers on Szot's departure. The departure of a CFO is material to investors assessing financial reporting oversight and continuity.
View raw filing on EDGAR →The filing discloses Item 5.07 (Submission of Matters to a Vote of Security Holders), reporting that the Special Meeting held on June 3, 2026 failed to achieve quorum and was adjourned to June 12, 2026. While technically a failure to achieve quorum rather than vote results, this is the closest matching event type under the taxonomy, as it concerns a stockholder meeting and voting process. The disclosure is material because it affects the timing and outcome of shareholder actions.
View raw filing on EDGAR →The company disclosed on June 3, 2026 that it is "exploring strategic alternatives," which signals potential material corporate action such as a sale, merger, restructuring, or other significant strategic change. While the specific nature of the alternatives is not detailed in this Item 7.01 disclosure, the announcement itself is material to investors as it indicates the company is considering fundamental changes to its business or structure. This does not fit neatly into the M&A taxonomy categories (which typically require entry into, completion, or termination of a transaction) but represents a material event that would affect investor assessment of the registrant's future direction.
View raw filing on EDGAR →The filing discloses the Company's intention to pursue a Commissioner's National Priority Review Voucher contingent on positive interim/final analysis results from its tafenoquine trial in severe babesiosis patients, with potential NDA submission targeted before Q1 2028. This represents a material regulatory development plan for a clinical-stage pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or other defined event types). The disclosure is material to investors assessing the company's development pipeline and regulatory strategy, warranting classification as other_material.
View raw filing on EDGAR →The filing discloses the departure of Jaret Christopher as Chief Executive Officer and director of SpringBig Holdings, Inc., effective May 28, 2026. The Separation Agreement specifies severance terms including two months of base salary continuation, COBRA premiums, and a $50,000 cash payment. The departure of a CEO is material to investors as it affects corporate leadership and governance.
View raw filing on EDGAR →Silo Pharma, Inc. implemented a 1-for-15 reverse stock split of its Common Stock, effective June 2, 2026, which proportionately reduced the Company's issued, outstanding, and authorized shares. This capital structure change affects share price, option and warrant exercise prices, and equity plan reserves, and may reflect efforts to address listing compliance requirements.
View raw filing on EDGAR →The disclosure centers on the Compensation Committee's approval and adoption of an Amended and Restated Change in Control Severance Agreement on June 1, 2026, which modifies severance arrangements for named executive officers including CFO Conor Tierney. This is a compensatory arrangement modification affecting severance benefits and is material to investors assessing executive retention and potential costs of separation events.
View raw filing on EDGAR →The disclosure announces the Company's focus on a potential business combination with a target in Venezuela's upstream oil and gas sector, specifically brownfield redevelopment of mature producing fields. While the transaction is still in preliminary stages (non-binding term sheet, no definitive agreement), the announcement of a strategic focus on a material acquisition target and the negotiation of a $2.25 billion committed equity facility to support the transaction constitute material M&A activity under Item 1.01 framework. The Company is a SPAC-like entity seeking to complete an initial business combination, making this strategic pivot and financing arrangement material to investors.
View raw filing on EDGAR →Marshall S. McCrea III, Co-Chief Executive Officer of Energy Transfer LP, notified the Partnership on June 1, 2026 of his intention to retire effective on or before December 31, 2026. While the filing also discloses compensatory arrangements (acceleration of equity awards and a separation agreement), the principal disclosed action is McCrea's departure from the Co-CEO role, with Thomas E. Long assuming sole CEO responsibilities. This is material as it involves a change in executive leadership at a major energy partnership.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Amphastar's Annual Meeting held on June 3, 2026. The filing reports voting outcomes on four proposals: election of three Class I directors (David Gaugh, William J. Peters, and Jacob Liawatidewi), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (approved at one-year intervals). All proposals passed with substantial majorities, making this a material governance event that investors rely upon to assess board composition and compensation oversight.
View raw filing on EDGAR →Douglas Emmett held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on four proposals: election of directors, ratification of Ernst & Young LLP as auditors, advisory vote on named executive officer compensation, and approval of the 2026 Omnibus Stock Incentive Plan. The filing discloses detailed vote tallies for each proposal.
View raw filing on EDGAR →The filing discloses Veeva Systems' first quarter financial results for the period ended April 30, 2026, via a press release furnished as Exhibit 99.1. This is a standard quarterly earnings release under Item 2.02, which is material to investors as it provides current financial performance and operational results.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of PubMatic's annual meeting of stockholders held on May 29, 2026. The filing presents voting results for three proposals: election of eight directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final voting results from Bright Horizons' annual meeting of shareholders held on June 3, 2026. The filing presents tabulated results for three proposals: election of six directors, advisory vote on named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a material shareholder governance event.
View raw filing on EDGAR →Nuo Therapeutics entered into an Amended and Restated Loan and Security Agreement on May 29, 2026, increasing aggregate commitments to $2.0 million with $675,000 funded at interim closing and $325,000 committed for future funding. The transaction involves insider lenders (Scott Pittman, a director and 10%+ owner, and Paul Jacobs, a 5%+ owner), a security interest in all Company assets, and significant warrant dilution (120,125+ immediately exercisable shares plus contingent warrants), representing a material capital structure event.
View raw filing on EDGAR →Astrotech entered into an at-the-market (ATM) offering agreement with H.C. Wainwright & Co. on June 2, 2026, authorizing the sale of up to $24.5 million in common stock shares. ATM offerings are classic dilutive equity issuances that allow continuous market sales and represent a material capital-raising activity that would affect investor assessment of share dilution and the company's financial position.
View raw filing on EDGAR →TG Therapeutics disclosed positive Phase 1 clinical trial data for a subcutaneous formulation of ublituximab (BRIUMVI®) in relapsing multiple sclerosis. While clinical trial results can be material to investors assessing pipeline value and competitive positioning, this disclosure does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The positive PK/PD and safety data would reasonably affect an investor's assessment of the company's drug development prospects, warranting classification as other_material.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 2, 2026, filed under Item 5.07. The filing reports voting outcomes on four proposals: election of Class III Directors (Paul Oroian, Virginia Prodan, Pandji Putra, and Robert Dunn), ratification of RBSM, LLP as auditors, approval of named executive officer compensation, and frequency of future advisory votes on compensation. These are standard annual meeting matters that materially affect corporate governance and investor interests.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Mannatech's 2026 Annual Shareholders' Meeting held on June 2, 2026. The filing reports voting outcomes on three proposals: election of directors (John A. Seifrick and Robert Toth as Class III directors), ratification of BDO USA, P.C. as independent auditor, and advisory approval of executive compensation. The detailed vote tallies and broker non-votes are presented in tabular form, which is the standard format for Item 5.07 disclosures of shareholder meeting results.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of CEVA's June 2, 2026 annual stockholder meeting, including voting outcomes for three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of independent auditors. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →TaoWeave entered into a Technology License and Distribution Agreement with Manako Labs on May 28, 2026, establishing an integration partnership combining Manako's AI platform with TaoWeave's commercial infrastructure. Concurrently, TaoWeave made a $1,000,000 equity investment in Manako via a SAFE, with the commercial obligations becoming operative upon full payment (completed May 29, 2026). The filing discloses Item 1.01 (Entry into a Material Definitive Agreement), and the transaction involves material consideration ($1M investment plus warrant issuance up to 300,000 shares), multi-year licensing rights, and revenue-sharing arrangements—characteristics of a material strategic partnership or acquisition-like arrangement that would affect investor assessment of the company's direction and financial commitments.
View raw filing on EDGAR →IDT Corporation issued a press release on June 3, 2026 announcing results of operations for its fiscal quarter ended April 30, 2026, filed under Item 2.02 of Form 8-K. The disclosure explicitly states the earnings release is furnished as Exhibit 99.1, which is the standard mechanism for disclosing quarterly financial results. Earnings releases are material to investors as they provide essential information about the registrant's financial performance.
View raw filing on EDGAR →SPAR Group issued 3,190,569 shares of common stock to ReposiTrak in satisfaction of a $2.325 million debt obligation under a services agreement. This unregistered equity issuance under Section 4(a)(2) and Regulation D materially dilutes existing shareholders' ownership.
View raw filing on EDGAR →